The International Scientific Advisory Board

INCa’s international scientific Advisory board monitors the consistency of the Institute’s scientific and medical policies. It has been chaired by Prof Jacques Pouyssegur since 5 November 2007. It is made up of 21 internationally recognised experts appointed by the relevant ministers. Every year it publishes a scientific report.
It meets at least once a year and issues recommendations regarding the Institute’s scientific policy

Members of the International Scientific Advisory Board

Biographies

James ARMITAGE
Dr. James O. Armitage is a graduate of the University of Nebraska Medical Center. He developed and directed the Bone Marrow Transplant program at the University of Iowa and later at the University of Nebraska where he also served as Vice-Chair of Internal Medicine, Chair of Internal Medicine, Dean of the College of Medicine at Nebraska and currently is the Joe Shapiro Professor of Medicine in the section of Oncology/Hematology. He is an expert of the Non-Hodgkin's Lymphoma.

Retour

Jean-Pierre BIZARRI
Dr Bizzari holds a medical degree from the University of Nice (France) and trained as an oncologist at the Pitie Salpetriere hospital in Paris. He joined the pharmaceutical industry in 1983 and, since October 2008, has been Senior Vice President Clinical Development Oncology at Celgene.

Retour

Nancy E. DAVIDSON
Nancy E. Davidson, MD, is internationally renowned for her research involving breast cancer. She has published key findings on the role of hormones, particularly estrogen, on gene expression and cell growth in breast cancer and has guided several important national clinical trials of potential new therapies, including chemoendocrine therapy for premenopausal breast cancer and antiangiogenesis therapy for advanced disease.
Prior to joining the University of Pittsburgh Cancer Institute and UPMC Cancer Centers, she served as director of the Johns Hopkins Kimmel Cancer Center’s Breast Cancer Program in Baltimore and as professor of oncology at Johns Hopkins School of Medicine. Dr. Davidson recently served as president of the American Society of Clinical Oncology and is a member of the scientific advisory board of numerous foundations.
Retour

Olivier DELATTRE
First a paediatrician and then a molecular biologist, Olivier Delattre was recruited at the Inserm in 1991, where he is director of the “Genetics and biology of cancer” department. Since 2009, he has also been delegate director for biomedical research of the Institut Curie Research Center.
His main research interests are the characterization and the functional studies of the genetic abnormalities that are found in cancer cells. His team unravelled key genetic alterations in Ewing’s sarcoma, rhabdoid tumours and neuroblastoma.
He is heading the group “Genetics and biology of pædiatric tumours and of sporadic breast cancers”.
He is member of several Scientific Boards, among which, the Fondation Jean Dausset (2007) and the Cancer Genome Project of the Welcome Trust Sanger Institute (2008).

Retour

Anne EICHMANN
Anne Erichmann is director of Research at the laboratory of vascular development at Inserm U36, Collège de France, Paris
Her research interests are mainly the mechanisms of specifications of endothelial precusors into hematopoietic cells and the study of participation of endothelial precusors in tumoral angiogenesis.
Her basic research is linked to a research conducted in collaboration with clinicians and industrial partners, and focuses on therapeutic tools for anti-angiogenic treatment.

Retour

Judy GARBER
Judy E. Garber, MD MPH is the Leader of the Center for Cancer Genetics and Prevention at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. She is president-elect of the American Association for Cancer Research.
Dr. Garber is a medical oncologist and clinical cancer geneticist.  Her work has focused particularly on the genetics of breast and ovarian cancer, and the management of individuals at increased risk.  Dr. Garber received her MD and MPH from Yale University School of Medicine.

Retour

Jean-Luc HAROUSSEAU
Jean-Luc Harousseau is Professor of Hematology at the University of Nantes, France.
He has been Head of the Department of Clinical Haematology for 24 years and is now Director of the Cancer Center René Gauducheau (Nantes). He was a founder member of the Groupe Ouest-Est Leucémies Aigues et Maladies du Sang and of the Intergroupe Français du Myélome and is currently President of this internationally renowned cooperative group.
His fields of interest are Therapy of Acute Myeloid Leukemia and of Multiple Myeloma.
He received the 2009 Robert Kyle Award for his scientific contribution in the field of Multiple Myeloma.

Retour

Denis HEMON
Director of research (Inserm), Denis Hémon is the director the Center of Public Health Studies. He is also the director of the Doctoral school « Santé publique Paris Sud 11, Paris Descartes ».
He was vice-president of the Inserm scientific advisory board from 2003 to 2007.
Denis Hémon is an expert in environmental epidemiology, cancer epidemiology and in methodology for epidemiology studies.

Retour

Jean-Marie LEHN

Retour

Daniel LOUVARD
Daniel Louvard is Research Director at CNRS, Professor at Institut Pasteur, Director of the Research Center of Institut Curie. He is member of EMBO and of Academies such as the French and the European Academy of Sciences and the European Academy of Cancer Sciences.
He is a biochemist and a cell biologist. His basic research is focused on the functions of epithelia. More recently, he has developed new research on transgenic mice and analyzed the molecular basis of carcinogenesis of the digestive epithelium with the goals to develop new diagnostic and therapeutic approaches.

Retour

Bernard MALISSEN
Bernar Malissen is Director of research CNRS and director of the Immunology Center - Marseille Luminy. Bernard Malissen specializes in molecular immunology. His research interests are the mechanisms for T-Lymphocytes antigene recognition. He is specialised in the studies of the lymphocyte T receptor.

Retour

Theresa MARTEAU
Theresa Marteau is Professor of Health Psychology at King's College, London, Fellow of Hughes Hall, Cambridge and visiting academic at the National Institute of Health, USA and the University of Cambridge. She is a Fellow of the Academy of Medical Sciences and the Academy of Learned Societies for the Social Sciences.
Her research focuses on the emotional, cognitive and behavioural responses to health risk information, organised around two broad themes: Risk Communication and Behaviour; and Informed Choice and Behaviour. The behaviours studied include screening, smoking, diet, and physical activity.
She is currently developing a programme of research evaluating the use of incentives to improve population health, from the perspectives of psychology, economics and ethics.

Retour

Michel MARTY
Michel Marty, Professor of Medical Oncology at University Paris VII, was Head of the Medical Oncology Dpt at St Louis Hospital in Paris for 19 years, before becoming Director of Therapeutic Research at Institut Gustave Roussy. Since 2005, he has been Head of Therapeutic Innovations at St Louis Hospital in Paris.
Michel Marty is also Chairman of the antineoplastic agents working group of the French National Drug Agency (AFSSAPS) and Chairman of the Scientific Advisory Group Oncology in the Commission for Human Medicinal Products in London.

Retour

Patrick MEHLEN
Patrick Mehlen is Director of the Laboratory “Apoptosis, Cancer and Development” – CNRS and co-Director of the Institute for Clinical Science at the Cancer Center, Léon Bérard in Lyon.
His main research interest is the role of the small stress protein in apoptosis. In 1996, he joined the CNRS to carry out research in this topic and since then, his laboratory has remained at the forefront on the role of dependence receptors in cell death.

Retour

Jacques POUYSSÉGUR, Chairman
Jacques Pouysségur, PhD, spent several years as a post –doctoral scientist at the University of Leicester – England,  at the NCI, the San Francisco University and the Whitehead Institute of Cambridge – USA. He  established his own research group in 1980 at the CNRS Biochemistry Centre of the University of Nice. He then contributed to the development of the Institute of Signaling, Developmental Biology and Cancer Research, a CNRS Unit, housing 14 Group Leaders at the Lacassagne Cancer Center & University of Nice, that he directed from 1997 to 2008.
His group has been interested for the last 10 years in hypoxia signalling, related to angiogenesis, nutrient sensing and tumour metabolism. Jacques Pouyssegur is also Chairman of the Scientific Board of the Institut Claudius Regaud in Toulouse.

Retour

Jean-Charles SORIA

Jean-Charles Soria is Professor of Medecine and Medical Oncology at Paris University XI. He is a cancer specialist at Institut Gustave Roussy where he is currently Head of the phase I programme and member of the lung cancer unit with a focus on targeted therapies. Jean-Charles Soria gained a PhD degree in the fundamental basis of oncogenesis in 2001, and completed his training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, Houston, USA. He is currently involved in translational research aspects related to tumor progression notably in lung cancer models. Dr Soria was a member of ESMO executive committee from 2008 to 2009.

Retour

Michaël STRATTON
Michael Stratton is Deputy Director of the Wellcome Trust Sanger Institute, where he is Head of the Cancer Genome Project, and is Professor of Cancer Genetics at the Institute of Cancer Research. He qualified in medicine at Oxford University and Guys Hospital, trained as a histopathologist at the Hammersmith and Maudsley Hospitals and obtained a PhD in the molecular biology of cancer at the Institute of Cancer Research.
His research interests have been in the genetics of cancer. He led the group that mapped and identified the high risk breast cancer susceptibility gene, BRCA2. More recently he has found moderate risk breast cancer susceptibility genes such as CHEK2, ATM, BRIP and PALB2 as well as genes for skin, testis, colorectal, thyroid, and childhood cancers.
At the Cancer Genome Project he conducts high throughput, systematic genome-wide searches for somatic mutations in human cancer in order to identify new cancer genes, to understand processes of mutagenesis in human cancers and to reveal the role of genome structure in determining abnormalities of cancer genomes. These studies have led to the discovery of activating somatic mutations in the BRAF and ERBB2 genes in melanoma and lung cancer respectively and have described basic patterns of somatic mutation in cancer genomes. He was elected a Fellow of the Royal Society in 2008.

Retour

Albert VAN DER KOGEL
Albert van der Kogel is Professor of Clinical Radiobiology and Head of Laboratory for Experimental Radiotherapy, Dept. Radiation Oncol, Radboud University Nijmegen Med Ctr, The Netherlands. His research interests are the mechanisms and the radiation tolerance studies of central nervous system as well as the molecular and functional immunofluorescent imaging of the tumor microenvironment, with emphasis on hypoxia and related signaling pathways.
Professor van der Kogel is also Editor for biology in the journal Radiotherapy and Oncology and Director, ESTRO Teaching course of Basic Clinical Radiobiology.

Retour

Bruno VARET
Bruno Varet is Professor of Hematology at the Ecole de Medicine – Paris Descartes University.
He is a Clinical Hematologist and was until 2009, Head of Hematology, Immunology and Infectious diseases Dept (Children and adults) at Necker-Enfants Malades Hospital AP-HP Paris.
Bruno Varet is President of the Working Group for Cellular Therapy at AFSSAPS and Vice-President of the Paris Descartes University Scientific Board.
His research interests focus on Erythropoïesis, Erythropoïetin, Myeloïde differenciation and transformation (CNRS URA/UMR Necker).

Retour

Robert WEINBERG
Robert A. Weinberg is Professor of biology at the M.I.T. in Cambridge, USA. A Founding Member of Whitehead Institute, Robert Weinberg is a pioneer in cancer research most widely known for his discoveries of the first human oncogene – a gene that causes normal cells to form tumors – and the first tumor suppressor gene.
Today, his laboratory focuses on the molecular mechanisms behind tumor formation. Robert Weinberg’s research is divided into three main areas: invasion and metastasis; cell death; and the processes by which epithelial and stromal cells, the two primary types of cells found in mammalian tissue, interact in tumors. He considers metastasis and invasion to be the "last frontier of cancer research", since researchers know very little about how tumors manage to colonize distant sites in the body.

Retour

Otmar D. WIESTLER
Prof. Dr. Otmar D. Wiestler is Chairman of the Management Board and Scientific Director of the German Cancer Research Center in Heidelberg (DKFZ).
Since 2004, he has also been Chairman of the Advisory Committee and member of the Board of the German Cancer Aid and since 2007 Vice-President of the Helmholtz Association of German Research Centres.
Prof. Dr. Wiestler, studied medicine at the University of Freiburg, where he was awarded his doctoral degree in 1984. From 1984 to 1987 Pr. Wiestler joined the Department of Pathology at the University of California in San Diego as a postdoctoral researcher. In 1987 he moved to the Department of Pathology at the University of Zurich, Switzerland where he completed his Habilitation in pathology.
From 1992 to 2003 he headed the Department of Neuropathology at the University of Bonn, where he also served as head of the German Brain Tumor Reference Center, as coordinator of the collaborative research center SFB 400, and as medical director of Life & Brain GmbH.

Retour